TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
Healthcare
$0.82 +2.23%
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
52W Low $0.85High $2.57
Volume 0.00M
Average 0.81M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$135.32M
FY 2025 · Annual
Investing Cash Flow
$109.37M
FY 2025 · Annual
Financing Cash Flow
-$336,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| Deferred Income Tax | (9.16M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.52M | 4.55M | 5.21M | 9.55M | 11.71M |
| Change in Working Capital | (5.9M) | (10.23M) | 17.61M | 5.05M | (18.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10K | 528K | (52K) | 1.99M | (3.01M) |
| Other Working Capital | (5.91M) | (10.76M) | 17.66M | 3.06M | (15.17M) |
| Other Non-Cash Items | 9.16M | 260K | (315K) | (2.03M) | (1.95M) |
| Operating Cash Flow | (48.68M) | (66.5M) | (61.36M) | (110.82M) | (135.32M) |
| Capital Expenditures | (9.94M) | (4.23M) | (3.15M) | (3.83M) | (4.41M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (77.61M) | (241.45M) | (87.47M) |
| Sales of Investments | 0 | 0 | 20M | 192.66M | 201.25M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.94M) | (4.23M) | (60.76M) | (52.61M) | 109.37M |
| Debt Repayment | 0 | 29.35M | 0 | 15.31M | 0 |
| Common Stock Issued | 89.65M | 193K | 42.41M | 33.13M | 264K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 291K | (191K) | 93.03M | 160.32M | (600K) |
| Financing Cash Flow | 189.67M | 29.36M | 135.44M | 208.77M | (336K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 131.05M | (41.37M) | 13.33M | 45.33M | (26.28M) |
| Free Cash Flow | (58.62M) | (70.73M) | (64.5M) | (114.65M) | (139.73M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$129.8M
+ D&A$2.9M
+ Stock-Based Comp$11.7M
+ Deferred Tax$0
- Working Capital-$18.2M
- Other Non-Cash-$1.9M
= Operating Cash Flow-$135.3M
- Capex-$4.4M
= Free Cash Flow-$139.7M
Analysis
FY2025 free cash flow is -$139.7M. FCF conversion is 107.7% of net income. Operating cash flow was -$135.3M, with capex of -$4.4M. The largest bridge item is Working Capital at -$18.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jun 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 8-K | Current report | May 22, 2026 |
Does TCRX generate free cash flow?
TScan Therapeutics, Inc. (TCRX) generated -$139.73M of free cash flow in fiscal 2025.
How much operating cash flow does TCRX produce?
Operating cash flow was -$135.32M, before capital expenditures of $4.41M.
Continue the stock analysis
Jump to another research area for this company.